Neil A Accortt
Overview
Explore the profile of Neil A Accortt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
649
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jin R, Ogbomo A, Accortt N, Lal L, Bishi G, Sandschafer D, et al.
Ther Adv Med Oncol
. 2023 Jun;
15:17588359231182386.
PMID: 37360769
Background: Bevacizumab-awwb (MVASI) was the first U.S. Food and Drug Administration-approved biosimilar to Avastin (reference product [RP]) for the treatment of several different types of cancers, including metastatic colorectal cancer...
2.
Rhodes W, DeClue R, Accortt N, Jin R, Sandschafer D, Wertz D, et al.
Future Oncol
. 2021 Oct;
17(36):5119-5127.
PMID: 34698523
Evaluated real world use of bevacizumab-awwb (MVASI), a bevacizumab biosimilar, for treating metastatic colorectal cancer (mCRC). Adult mCRC patients who received bevacizumab-awwb during the first year after market availability were...
3.
Sauer B, Chen W, Xu Y, Shen J, Accortt N, Collier D, et al.
Arthritis Res Ther
. 2020 Oct;
22(1):253.
PMID: 33092642
Background: A previous analysis of the Veterans Affairs Rheumatoid Arthritis (VARA) registry showed that more than half of the patients with rheumatoid arthritis (RA) did not receive a major therapeutic...
4.
Pappas D, Shan Y, Lesperance T, Kricorian G, Karis E, Rebello S, et al.
ACR Open Rheumatol
. 2020 Sep;
2(10):588-594.
PMID: 32990361
Objective: The purpose of this study was to evaluate maintenance of remission/low disease activity (LDA) in patients with rheumatoid arthritis (RA) who achieved remission/LDA with etanercept (ETN) plus a conventional...
5.
Pappas D, Litman H, Lesperance T, Kricorian G, Karis E, Rebello S, et al.
Rheumatol Int
. 2020 Sep;
41(2):381-390.
PMID: 32876744
Biological disease-modifying antirheumatic drugs (bDMARDs) monotherapy may enhance adherence and decrease adverse events compared to combination therapy with conventional synthetic DMARDs (csDMARDs); however, persistence with bDMARD monotherapy has not been...
6.
Zhang J, Sridhar G, Barr C, Eichelberger B, Lockhart C, Marshall J, et al.
J Manag Care Spec Pharm
. 2020 Apr;
26(4):417-490.
PMID: 32223608
Background: There is a need for postmarketing evidence generation for novel biologics and biosimilars. Objective: To assess the feasibility, strengths, and limitations of the Biologics and Biosimilars Collective Intelligence Consortium...
7.
Sauer B, Chen W, Shen J, Accortt N, Collier D, Cannon G
Arthritis Care Res (Hoboken)
. 2020 Mar;
73(7):964-974.
PMID: 32166882
Objective: To examine the impact of major therapeutic change (MTC) on clinical response across a broad range of disease activity in US veterans with rheumatoid arthritis (RA). Methods: This historical...
8.
Mease P, Accortt N, Rebello S, Etzel C, Harrison R, Aras G, et al.
Rheumatol Int
. 2019 Jul;
39(9):1547-1558.
PMID: 31321485
This study described treatment patterns in a psoriatic arthritis (PsA) patient registry for new or ongoing tumor necrosis factor inhibitor (TNFi) monotherapy, conventional synthetic disease-modifying antirheumatic drug (csDMARD) monotherapy, or...
9.
Pappas D, Rebello S, Liu M, Schenfeld J, Li Y, Collier D, et al.
J Rheumatol
. 2019 Apr;
46(11):1438-1444.
PMID: 30936285
Objective: Guidelines suggest that rheumatoid arthritis (RA) patients with previously treated solid malignancy may be treated as patients without such history. The recommendation is based on limited evidence, and rheumatologists...
10.
Paller A, Schenfeld J, Accortt N, Kricorian G
Pediatr Dermatol
. 2019 Feb;
36(3):290-297.
PMID: 30791141
Background/objective: Compared with the adult psoriasis population, knowledge about the incidence of comorbidities in the pediatric psoriasis population is limited. The objective of this study was to assess the prevalence...